Abbott
At Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world - in nutrition, diagnostics, medical devices and branded generic pharmaceuticals - that create more possibilities for more people at all stages of life. Today, 73,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.
Business & Industry
- FDA authorises restart of the COVID-19 AZD1222 vaccine US Phase III trial
- CureVac reports positive preclinical data for its COVID-19 vaccine candidate, CVnCoV
- Moderna completes enrollment of Phase 3 COVE study of mRNA vaccine against COVID-19 (mRNA-1273)
- Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies
- Regeneron's REGN-COV2 antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients
Research & Development
- Oxford COVID-19 vaccine follows its programmed genetic instructions, independent analysis finds
- Study finds tocilizumab improves survival in critically ill patients with COVID-19
- Work to develop a COVID-19 vaccine is faster than ever
- A vaccine project funded by the Federal Ministry for Economic Affairs and Energy develops a second generation COVID-19 vaccine
- NIH begins large clinical trial to test immune modulators for treatment of COVID-19
- Scientists identify common vulnerabilities across SARS-CoV-2, SARS-CoV-1 and MERS coronaviruses
- Popular COVID-19 conspiracies linked to vaccine 'hesitancy'
Conferences & Events
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
- COVID-19 vaccine innovation could dramatically speed up worldwide production
- Wearable Injectors and Connected Devices Conference 2020
Regulatory Affairs
- FDA approves first treatment for COVID-19
- Investigational COVID-19 vaccine well-tolerated, generates immune response in older adults
- EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation
- FDA issues emergency use authorization for convalescent plasma as potential promising COVID-19 treatment
- FDA Takes Action to Help Facilitate Timely Development of Safe, Effective COVID-19 Vaccines